Is it fair to say that the breath of leronmimab in generating T cell (NK cells are a type of T cell?) killing of tumor cells along with macrophage polarization and support along with moderation of excessive inflammation along with reduction of metastasis along with PD-1 upregulation means that it should be much more effective and broad against cancer than ANKtiva?